The potential of BCL-xL degradation as a strategy to eliminate chemotherapy-resistant neuroblastoma persister cells
Monday, April 28, 2025
2:30pm – 2:45pm HST
Location: Convention Center: 327
Publication Number: 4100.3
Matteo Calafatti, Boston Children's Hospital, Boston, MA, United States; Emily A. Mycek, Children’s Hospital of Philadelphia, Norristown, PA, United States; Dana Al-Halawani, Childrens Hospital of Philadelphia, Philadelphia, PA, United States; Joshua R. Kalna, Childrens Hospital of Philadelphia, Philadelphia, PA, United States; David N. Groff, Childrens Hospital of Philadelphia, Newark, DE, United States; Esther Coronado Mondragon, Childrens Hospital of Philadelphia, Philadelphia, PA, United States; Khushbu Patel, Childrens Hospital of Philadelphia, Woodstock, GA, United States; Mark Gerelus, Children's Hospital of Philadelphia, Philadelphia, PA, United States; Jarrett Lindsay, University of Pennsylvania, Philadelphia, PA, United States; Kyabeth Torres-Rodríguez, Children’s Hospital of Philadelphia, Philadelphia, PA, United States; Skye Balyasny, Children's Hospital of Philadelphia, Philadelphia, PA, United States; Smita Matkar, Childrens Hospital of Philadelphia, Philadelphia, PA, United States; Yael P. Mossé, Children's Hospital of Philadelphia, Philadelphia, PA, United States; Liron D. Grossmann, Sheba Medical Center, Tel Aviv, Tel Aviv, Israel; John M. Maris, The Children's Hospital of Philadelphia, Philadelphia, PA, United States; jaime Font de Mora, Instituto de Investigación Sanitaria La Fe. Hospital La Fe, Valencia, Comunidad Valenciana, Spain
Presenting Author(s)
Matteo Calafatti, MD (he/him/his)
Pediatric Resident Physician Boston Children's Hospital / Boston Medical Center Boston, Massachusetts, United States
Disclosure(s):
Matteo Calafatti, MD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
